Benderitter Marc, Pourcher Thierry, Martin Jean-Charles, Darcourt Jacques, Guigon Pierre, Caire-Maurisier Francois, Pech Annick, Lebsir Dalila, Rosique Clément, Guglielmi Julien, Rebière Francois, Tack Karine, Phan Guillaume, Lestaevel Philippe, Souidi Maâmar, Jourdain Jean-René
Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-Santé, Fontenay-aux-Roses, France.
Laboratoire BIAM/TIRO, Commissariat à l'Energie Atomique et aux énergies alternatives (CEA), School of medicine, 28 avenue de Valombrose, Nice, France.
Radiat Prot Dosimetry. 2018 Dec 1;182(1):67-79. doi: 10.1093/rpd/ncy129.
Single dose of potassium iodide (KI) is recommended to prevent the risk of thyroid cancer during nuclear accidents. However in the case of repeated/protracted radioiodine release, a unique dose of KI may not protect efficiently the thyroid against the risk of further developing a radiation-induced cancer. The new WHO guidelines for the use in planning for and responding to radiological and nuclear emergencies identify the need of more data on this subject as one of the four research priorities. The aims of the PRIODAC project are (1) to assess the associated side effects of repeated intakes of KI, (2) to better understand the molecular mechanisms regulating the metabolism of iodine, (3) to revise the regulatory French marketing authorization of 65-mg KI tablets and (4) to develop new recommendations related to the administration of KI toward a better international harmonization. A review of the literature and the preliminary data are presented here.
建议单次服用碘化钾（KI）以预防核事故期间甲状腺癌的风险。然而，在反复/长期释放放射性碘的情况下，单次服用KI可能无法有效保护甲状腺免受进一步发展为辐射诱发癌症的风险。世界卫生组织关于应对放射性和核紧急情况规划与响应的新指南确定，关于这一主题的更多数据需求是四个研究重点之一。PRIODAC项目的目标是：（1）评估重复摄入KI的相关副作用；（2）更好地理解调节碘代谢的分子机制；（3）修订法国65毫克KI片剂的监管上市许可；（4）制定与KI给药相关的新建议，以实现更好的国际协调。本文介绍了文献综述和初步数据。
